<DOC>
	<DOCNO>NCT00449813</DOCNO>
	<brief_summary>The aim study compare two different endpoint measure : heartburn assess physician versus gastroesophageal reflux disease ( GERD ) -related symptom assess patient use ReQuestâ„¢ questionnaire . The assessment make GERD-patients treated daily dose 40 mg oral pantoprazole 8-week period .</brief_summary>
	<brief_title>The CONQUEST-Study . Evaluation Clinical Endpoints Treatment-induced Changes GERD-related Symptoms ( BY1023/NL511 )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Written inform consent Outpatients least 18 year age History GERDrelated symptoms least 6 month prior baseline visit Endoscopicallyconfirmed GERD nonerosive GERD ZollingerEllison syndrome gastric hypersecretory condition Acute peptic ulcer and/or ulcer complication Pyloric stenosis Severe unstable cardiovascular , pulmonary , and/or endocrine disease Pregnancy , breast feeding , intention become pregnant course study lack reliable contraception woman childbearing potential Intake medication purpose eradication Helicobacter pylorus ( H. pylorus ) within last 28 day prior study start Intake systemic glucocorticoid nonsteroidal antiinflammatory drug include cyclooxygenase2 ( COX2 ) inhibitor 3 consecutive day within last 28 day prior study start ; exception acetylsalicylic acid 150 mg per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Gastroesophageal reflux disease ( GERD )</keyword>
	<keyword>Non erosive reflux disease ( NERD )</keyword>
</DOC>